Guillain-Barré syndrome in times of pandemics.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Ocular Surface Changes Associated with Neurological Diseases.Medicina (Kaunas, Lithuania) · 2025
   Review
2. Is there a difference between GBS triggered by COVID-19 and those of other origins?The Egyptian journal of neurology, psychiatry and neurosurgery · 2022
   Article
3. The legacy of ZikaPLAN: a transnational research consortium addressing Zika.Global health action · 2021
   Review
4. SARS-CoV-2 Infection and Guillain-Barré Syndrome.Pathogens (Basel, Switzerland) · 2021
   Review
5. Guillain-Barré syndrome in low-income and middle-income countries: challenges and prospects.Nature reviews. Neurology · 2021
   Review
6. Guillain-Barré Syndrome Outbreak in Peru 2019 Associated WithNeurology(R) neuroimmunology & neuroinflammation · 2021
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as